ArticleESMO real world data and digital oncology2024

Efficacy of cabozantinib and sunitinib for the treatment of intermediate/poor risk renal cell carcinoma based upon UK real-world data.

D Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.